A Phase I/IIa, Double-blind, Randomized, Placebo-controlled, Dose-escalation Clinical Study Evaluating Safety, Tolerability and Immunogenicity of Two Dose Levels of Recombinant Adenoviral Serotype Ad35 and Serotype Ad26 Vectors Expressing the Malaria Plasmodium Falciparum Circumsporozoite Antigen Administered as Heterologous Prime-boost Regimen, and Assessing Protective Efficacy of the Higher Dose in a Malaria Challenge Model in Unblinded Conditions.

Trial Profile

A Phase I/IIa, Double-blind, Randomized, Placebo-controlled, Dose-escalation Clinical Study Evaluating Safety, Tolerability and Immunogenicity of Two Dose Levels of Recombinant Adenoviral Serotype Ad35 and Serotype Ad26 Vectors Expressing the Malaria Plasmodium Falciparum Circumsporozoite Antigen Administered as Heterologous Prime-boost Regimen, and Assessing Protective Efficacy of the Higher Dose in a Malaria Challenge Model in Unblinded Conditions.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 06 Sep 2012

At a glance

  • Drugs Malaria vaccine (Primary)
  • Indications Falciparum malaria
  • Focus Adverse reactions
  • Sponsors Crucell
  • Most Recent Events

    • 31 May 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 07 Mar 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 28 Jul 2011 rewrote profile as the NCT records for this and profile 55211 had each been put into the opposite profile, deleted VANS history events as they were not relevant for this profile
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top